vACcine COnfidence amongst those living with alleRgy during the COVID pandemic (ACCORD): a scoping review protocol

• Research
• Open Access
• 
  

• Michael A. Golding, 
• Nicole Askin, 
• Ayel Luis R. Batac, 
• Kaitlyn A. Merrill, 
• Elissa M. Abrams, 
• Philippe Bégin, 
• Moshe Ben-Shoshan, 
• Erika Ladouceur, 
• Leslie E. Roos, 
• Vladan Protudjer & 
• Jennifer L. P. Protudjer 

Allergy, Asthma & Clinical Immunology volume 18, Article number: 83 (2022) 

Abstract

Background

Reports of allergic reactions to the COVID-19 vaccines have been documented, which may also contribute to hesitancy. Despite the low likelihood that the COVID-19 vaccine will trigger an allergic reaction, we and others have reported that families with allergy remain vaccine hesitant due to concerns of COVID-19-vaccine-triggered anaphylaxis.

Objective

To present our scoping review protocol, that will inform a forthcoming living scoping review in which we will investigate the peer-reviewed and grey literature on COVID-19 vaccine hesitancy and allergic disease and/or allergic reactions following a COVID-19 vaccine.

English Version of Clinical Practice Guidelines for the Management of Atopic Dermatitis 2021

GUIDELINES - Free Access

Hidehisa Saeki,Yukihiro Ohya,Junichi Furuta,Hirokazu Arakawa,Susumu Ichiyama,Toshio Katsunuma,Norito Katoh,Akio Tanaka,Yuichiro Tsunemi,Takeshi Nakahara,Mizuho Nagao,Masami Narita,Michihiro Hide,Takao Fujisawa,Masaki Futamura,Koji Masuda,Tomoyo Matsubara,Hiroyuki Murota,Kiwako Yamamoto-Hanada. 

J Dermatol. 2022 Aug 22. doi: 10.1111/1346-8138.16527.

Abstract

This is the English version of the Clinical Practice Guidelines for the Management of Atopic Dermatitis 2021. Atopic dermatitis (AD) is a disease characterized by relapsing eczema with pruritus as a primary lesion. In Japan, from the perspective of evidence-based medicine, the current strategies for the treatment of AD consist of three primary measures: (i) use of topical corticosteroids, tacrolimus ointment, and delgocitinib ointment as the main treatment of the inflammation; (ii) topical application of emollients to treat the cutaneous barrier dysfunction; and (iii) avoidance of apparent exacerbating factors, psychological counseling, and advice about daily life.

Pru du 1, the Bet v 1-homologue from almond, is a major allergen in patients with birch pollen associated almond allergy

ORIGINAL ARTICLE - Open Access

Stefan Kabasser, Nadja Crvenjak, Stefanie Schmalz, Tanja Kalic, Christine Hafner, Pawel Dubiela, Aleksandra Kucharczyk, Stanislawa Bazan-Socha, Mateusz Lukaszyk, Heimo Breiteneder, Christian Radauer, Merima Bublin

Clin Transl Allergy. 2022 Aug 8;12(8):e12177. doi: 10.1002/clt2.12177.

Abstract

Background

Almond allergy is common and can manifest in two different forms. Primary almond allergy has been reported to be associated with sensitization to almond legumin Pru du 6. In birchendemic regions, there is a link between birch-pollinosis which is likely based on a cross-reactive Bet v 1 homologue, a yet unidentified allergen in almond. Therefore, we sought to identify and characterize a Bet v 1-homologue in almond.

Methods

The expression of a Bet v 1 homologue in almond kernels was confirmed by mass spectrometry.

Diagnosis of Apis dorsata venom allergy: use of recombinant allergens of Apis mellifera and a passive basophil activation test

• Research
• Open Access
• 
  

• Peshala Gunasekara, 
• S. M. Handunnetti, 
• Sunil Premawansa, 
• E. W. R. A. Witharana, 
• Indra P. Ratnayake, 
• Pradeep Kaluarachchi, 
• Chandima Karunatilake, 
• R. K. S. Dias, 
• G. A. S. Premakumara, 
• W. M. D. K. Dasanayake, 
• Suranjith L. Seneviratne & 
• Rajiva de Silva 

Clinical and Molecular Allergy volume 20, Article number: 11 (2022) 

• details

Abstract

Background

Allergy to Apis dorsata (Giant Asian Honeybee) venom is the commonest insect allergy in Sri Lanka and South East Asia. However, laboratory diagnosis is difficult as the pure venom and diagnostic reagents are not commercially available.

Objective

This study assessed the use of four recombinant allergens of A. mellifera venom and the passive basophil activation test in the diagnosis of A. dorsata venom anaphylaxis.

Defining the normal range of fractional exhaled nitric oxide in children: one size does not fit all

Ran Wang, Stephen J. Fowler, Stephen W. Turner, Sarah Drake, Laura Healy, Lesley Lowe, Hannah Wardman, Miriam Bennett, Adnan Custovic, Angela Simpson, Clare S. Murray

ERJ Open Research 2022 8: 00319-2022; DOI: 10.1183/23120541.00319-2022

Abstract

Background 

The normal range of fractional exhaled nitric oxide (FENO) is influenced by demographic factors. However, single, fixed cut-off values are used for clinical interpretation in children despite rapid growth. We aimed to define the normal range of FENO during childhood and evaluate its utility in a diagnostic setting.

Method 

FENO percentile charts were developed using data from nonasthmatic children in a population-based birth cohort (Manchester Asthma and Allergy Study). Children were skin prick tested, FENO measured at the ages of 8, 11, 13–16 and 18 years and clinical information collected. This chart was externally validated in the Study of Eczema and Asthma to Observe the Influence of Nutrition (SEATON) cohort before being prospectively tested in symptomatic, treatment-naïve patients with suspected asthma in a diagnostic setting (Rapid Access Diagnostics for Asthma study).

Does allergen immunotherapy for allergic rhinitis prevent asthma?

Arshad SH. Does allergen immunotherapy for allergic rhinitis prevent asthma? Ann Allergy Asthma Immunol. 2022 Sep;129(3):286-291. doi: 10.1016/j.anai.2022.04.028. 

Abstract

Asthma and allergic rhinitis (AR) have overlapping clinical and pathologic features, sustained by an underlying T helper 2 bias, resulting in airway inflammation that extends from the nose to the lung. Children who are monosensitized often develop polysensitization over time, and they are at high risk of developing asthma. The effect of allergen immunotherapy (AIT) is allergen specific, resulting in symptom improvement and reduction in medication requirement. It is the only known treatment that alters the natural history of allergic disease and induces long-term remission. A bystander or allergen-nonspecific effect of AIT has also been proposed—that AIT to 1 allergen might reduce the risk of development of sensitization to other allergens. Furthermore, several observational studies and clinical trials, in seasonal (pollen) and perennial (house dust mite) AR, have investigated a protective effect of AIT to prevent asthma.

Management of Patients with Suspected or Confirmed Antibiotic Allergy. Executive Summary of Guidance from the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Society of Allergy and Clinical Immunology (SEAIC), the Spanish Society of Hospital Pharmacy (SEFH) and the Spanish Society of Intensive Medicine and Coronary Care Units (SEMICYUC)

Paño-Pardo JR, Moreno Rodilla E, Cobo Sacristan S, Cubero Saldaña JL, Periañez Párraga L, Del Pozo León JL, Retamar Genti P, Rodríguez Oviedo A, Torres Jaén MJ, Vidal-Cortes P, Colás Sanz C.  J Investig Allergol Clin Immunol. 2022 Sep 5:0. doi: 10.18176/jiaci.0859. 

Abstract

Suspected or confirmed antibiotic allergy is a frequently encountered clinical circumstance that influences antimicrobial prescribing and often leads to the avoidable use of less efficacious and / or more toxic or costly drugs than first-line antimicrobials. Optimizing antimicrobial therapy in patients with antibiotic allergy labels has become one of the priorities of antimicrobial stewardship programs (ASP) in several countries. This guidance document aims to make recommendations for the systematic approach to patients with suspected or confirmed antibiotic allergy based on current evidence. A panel of eleven members of involved Scientific Societies with expertise in the management of patients with suspected or confirmed antibiotic allergy formulated questions about the management of patients with suspected or confirmed antibiotic allergy.

SARS-CoV-2 Can Trigger Chronic Fatigue Syndrome

A study published in Nature Communications found that, even after mild coronavirus disease 2019 (COVID-19), a subset of patients will develop symptoms which meet the diagnostic criteria for myalgic encephalomyelitis/chronic fatigue syndrome.

• Article
• Open Access
• 
  

A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity

• C. Kedor, 
• H. Freitag, 
• L. Meyer-Arndt, 
• K. Wittke, 
• L. G. Hanitsch, 
• T. Zoller, 
• F. Steinbeis, 
• M. Haffke, 
• G. Rudolf, 
• B. Heidecker, 
• T. Bobbert, 
• J. Spranger, 
• H. D. Volk, 
• C. Skurk, 
• F. Konietschke, 
• F. Paul, 
• U. Behrends, 
• J. Bellmann-Strobl & 
• C. Scheibenbogen 

Nature Communications volume 13, Article number: 5104 (2022)

• details

Abstract

A subset of patients has long-lasting symptoms after mild to moderate Coronavirus disease 2019 (COVID-19). In a prospective observational cohort study, we analyze clinical and laboratory parameters in 42 post-COVID-19 syndrome patients (29 female/13 male, median age 36.5 years) with persistent moderate to severe fatigue and exertion intolerance six months following COVID-19. Further we evaluate an age- and sex-matched postinfectious non-COVID-19 myalgic encephalomyelitis/chronic fatigue syndrome cohort comparatively. Most post-COVID-19 syndrome patients are moderately to severely impaired in daily live. 19 post-COVID-19 syndrome patients fulfill the 2003 Canadian Consensus Criteria for myalgic encephalomyelitis/chronic fatigue syndrome. Disease severity and symptom burden is similar in post-COVID-19 syndrome/myalgic encephalomyelitis/chronic fatigue syndrome and non-COVID-19/myalgic encephalomyelitis/chronic fatigue syndrome patients. Hand grip strength is diminished in most patients compared to normal values in healthy. Association of hand grip strength with hemoglobin, interleukin 8 and C-reactive protein in post-COVID-19 syndrome/non-myalgic encephalomyelitis/chronic fatigue syndrome and with hemoglobin, N-terminal prohormone of brain natriuretic peptide, bilirubin, and ferritin in post-COVID-19 syndrome/myalgic encephalomyelitis/chronic fatigue syndrome may indicate low level inflammation and hypoperfusion as potential pathomechanisms.

Download PDF